Deepthi Bhupathi

发表

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models1

S. Baruchel, H. Yeger, F. Meng, 2018, Translational oncology.

14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatment.

F. Meng, C. Hart, Jessica D. Sun, 2011, Journal of medicinal chemistry.

Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity.

Clarissa C. Lee, Weiqun Li, M. V. Van Zandt, 2022, Journal of medicinal chemistry.

Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition

F. Meng, C. Hart, Jessica D. Sun, 2015, BMC Cancer.

Deletion mutational analysis of BMRP, a pro-apoptotic protein that binds to Bcl-2

Srinivas Malladi, K. Parsa, M. González-García, 2011, Molecular and Cellular Biochemistry.

Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

F. Meng, C. Hart, Jessica D. Sun, 2015, Cancer biology & therapy.

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302

P. Glazer, R. Anderson, F. Meng, 2011, Molecular Cancer Therapeutics.

Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.

F. Meng, C. Hart, Jessica D. Sun, 2015, American journal of cancer research.

Abstract 5497: An efficient clonogenic assay for cytotoxic drug screening

F. Meng, C. Hart, Deepthi Bhupathi, 2010 .

Abstract 2263: NADPH-cytochrome P450 reductase reduction of TH-302, a hypoxia-activated prodrug

F. Meng, C. Hart, M. Matteucci, 2010 .

Abstract 4134: Reversal of adenosine-mediated immune suppression by CB-708, an orally bioavailable and potent small molecule inhibitor of CD73

Clarissa C. Lee, Weiqun Li, F. Parlati, 2019, Immunology.